SHIMMER Trial Reports Positive Results
December 18, 2024 This week Cognition Therapeutics reported encouraging topline results from their Phase 2 clinical trial of CT1812, an investigational drug being studied in people with dementia with Lewy […]
Read More
Trial Results – Experimental Drug Shows Promising Results in Phase 2 Trial
November 14, 2024 Clinical trial results reported at a recent scientific conference suggest that the drug nilotinib may improve outcomes in people with dementia with Lewy bodies (DLB). Nilotinib is […]
Read More
LBD Clinical Trials around the World
November 5, 2024 2024 has been an exciting year for clinical trials for people with Lewy body dementia (LBD). Over the past year, you have heard a lot from the […]
Read More
Does kidney injury increase risk for LBD?
September 26, 2024 A new study published in the medical research journal Neurology suggests that sudden worsening of kidney function (referred to as “acute kidney injury”) may nearly double the […]
Read More
Special Research Topic: Right of Withdrawal – What Research Participants Need to Know
September 04, 2024 Clinical trials are the key to unlocking future treatments and preventive strategies for Lewy body dementia (LBD). Only by testing new medications in controlled experiments, called trials, […]
Read More
Eye on Prevention: Clues from Prostate Therapy
August 05, 2024 According to new research from the University of Iowa, medications used for prostate enlargement may provide clues to future strategies to prevent dementia with Lewy bodies (DLB). […]
Read More
New Research Suggests Skin Test Can Detect Dementia with Lewy Bodies
May 29, 2024 Many people who have dementia with Lewy bodies (DLB) experience delay and difficulty with receiving an accurate diagnosis, often seeing multiple specialists before being correctly diagnosed. In […]
Read More
New Research Supports Nuplazid (Pimavanserin) Use in Parkinson’s Disease Dementia
March 18, 2024 Hallucinations and delusions (also called psychosis) are prominent features of Lewy body dementia (LBD), occurring in both dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). […]
Read More
The U.S. Based DIAMOND Lewy™ Management Toolkit
Originally developed in the UK for dissemination via the National Health Service, the Diamond Lewy™ Management Toolkit provides a comprehensive overview of the management of the complex symptoms of Lewy body […]
Read More
Advancing the Science: New Research Frameworks Proposed for the Biology of Dementia with Lewy Bodies and/or Parkinson’s Disease
Two articles published on January 22, 2024, in The Lancet Neurology journal are proposing complementary but different research frameworks for biological definitions of Lewy body disease, a label reflecting the […]
Read More
Men are at greater risk for Lewy body dementia than women, but why? New study seeks answers
Ece Bayram, MD, PhD. Researcher from the Lewy Body Dementia Association’s Research Center of Excellence at University of California San Diego December 12, 2023 Research suggests men have a higher […]
Read More
Research Update: Digging Deeper into Caregiver Strain—LBD Care Partners Report Elevated Levels of High Blood Pressure, Depression, Chronic Back Pain, and Arthritis
November 3, 2023 Caring for a person with Lewy body dementia (LBD) can be very difficult, For example, cognitive changes in LBD are more likely to involve executive function and […]
Read More
Join LBDA in Supporting the National Plan to End Parkinson’s
Sometimes it feels like LBD is hidden in the shadows of two more common diseases – Alzheimer’s disease and Parkinson’s disease. But did you know that federal funding of LBD […]
Read More
A new biological test may revolutionize diagnosis of Parkinson’s disease and dementia with Lewy bodies
A hallmark brain change associated with both Parkinson’s disease and dementia with Lewy bodies (DLB) is the formation of Lewy bodies in brain cells; Lewy bodies are dense collections of […]
Read More
Clinical Trials: New Data and New Opportunities
April 5, 2023 This is an exciting time to follow clinical research in Lewy body dementia. This month we are highlighting updates from recent studies, along with new opportunities to […]
Read More
New Clinical Trial: NIA Awards $21M to Study Treatment for DLB
February 8, 2023 The U.S. National Institute on Aging (NIA), part of the National Institutes of Health (NIH), has awarded $21M for a clinical trial in people with dementia […]
Read More
Clinical Trial of E2027 in DLB Fails
At December’s Clinical Trials in Alzheimer’s Disease conference, Eisai reported that its clinical trial of E2027 in dementia with Lewy bodies (DLB) failed to meet its primary objective. Designed as […]
Read More
FDA Approves DaTscan for Dementia with Lewy Bodies
GE Healthcare recently announced the U.S. Food and Drug Administration (FDA) granted marketing approval for its imaging agent, DaTscan, for use in people with suspected dementia with Lewy bodies (DLB). […]
Read More
Mouse Model Study Offers Insights on Positive DLB Trial Results
All people with dementia with Lewy bodies (DLB) experience increasing problems with cognition. A very common issue is reduced attention, caused by loss of brain cells that release a chemical […]
Read More
Should Medicare pay for the new Alzheimer’s treatment?
When the FDA approved aducanumab for early Alzheimer’s disease, they also required an additional clinical trial to generate more data on its safety and effectiveness. (See LBDA’s earlier position statement […]
Read More